Kornimate/medical-research-clean huggingface dataset:
self-sampling for human papillomavirus (hpv) among patients receiving colposcopy

Conditions: HPV

Summary: this study seeks to compare the accuracy and acceptability of hpv testing self-sampling kit and standard clinician-sampling for hpv testing. the primary outcome of this study is the concordance between screening results on self-sampling kits compared to clinician-collected hpv test, pap smear results, and colposcopy. secondary endpoints will include acceptability of self-sampling and barriers to cervical cancer screening. these endpoints will be analyzed to try to circumvent barriers to the cervical cancer screening and ascertain whether self-sampling is a viable alternative.

the american cancer society estimates that 4,170 women in the united states (us) will die from cervical cancer in 2018 (siegel et al., 2018). screening can reduce cancer mortality by (1) detecting malignancies when they are more treatable and (2) for some tests, identifying precancerous lesions for removal (shieh et al., 2016). guidelines recommend cytology and/or hpv testing for cervical cancer screening among women ages 30-65 years, but screening rates are suboptimal (u.s. preventive services task force, 2018; saslow et al., 2012). to help bridge these gaps in screening, hpv self-sampling would be an alternative to clinical-sampling for hpv testing. however, there are concerns about the comparability and acceptability of self-sampling kits. the main objective of this study is to compare the test characteristics of the human papillomavirus (hpv) self-sampling kit versus clinician-sampled hpv testing for cervical cancer screening. potential participants will be identified from the penn state family and community medicine and obgyn clinics after it is determined that they have abnormal findings on their (clinician-sampled) pap/hpv test and require a follow-up colposcopy. the patient will be pre-screened by a study team member. if they are found to be eligible, a study team member will invite them to participate in the study. after a participant enrolls in the study, a self-sampling kit is mailed to their home along with a summary explanation of research consent form and instructional sheet. participants will be asked to complete the kit two weeks before or after their colposcopy, giving them a 28 day collection window. study team members will perform a follow-up survey after the sample is collected and provide reminder phone calls if needed.

Eligibility criteria:
inclusion criteria: * penn state health patient * has an intact cervix * found to have abnormal findings on pap/hpv test that requires a colposcopy * speaks, read, or writes well in english or spanish exclusion criteria: * pregnant * cognitively impaired * incarcerated * complete hysterectomy * history of cervical treatment for abnormal pap/hpv test (i.e. cryotherapy, loop electrosurgical excision procedure (leep))

Keywords: hpv self-sampling colposcopy cervical cancer cancer screening
the prevalence and predictors of gastrointestinal symptoms in children with attention deficit / hyperactivity disorder

Conditions: Attention Deficit Disorder With Hyperactivity; Gastrointestinal Diseases

Summary: this study is to examine the gut problems in children with attention deficit hyperactivity disorders (adhd) and is conducted by the department of psychiatry of alice ho miu ling nethersole hospital. children with adhd who attend our department will be recruited with their parents/guardians' consent. only the primary caregiver will be invited for an interview to assess the recruited children's gut problems, autistic features, emotional problems, diet pattern and medical history. the data will be compared with normal children who are recruited as control in local primary schools. the aim of this study is to know whether children with adhd have higher chance of gut problems, and to assess other factors associated with the linkage.


Eligibility criteria:
inclusion criteria: * the study group will be recruited if the following criteria are met: 1. aged 6 to 11 years old 2. children with a diagnosis of adhd made by psychiatrists according to diagnostic and statistical manual for mental disorder, fifth edition criteria 3. currently study in mainstream schools in hong kong the control group will be recruited if the following criteria are met: 1. age 6 to 11 years old 2. currently study in mainstream schools in hong kong 3. typically developing in good mental and physical health exclusion criteria: * for both groups, the participant will be excluded if the following criterion is met: 1. children who are suffering from mental retardation 2. children who are suffering from organic illnesses that affect gastrointestinal function 3. children who are suffering from severe mental illnesses 4. children who have ever received, or are currently on, medication for adhd 5. children who are currently taking medication for illnesses other than adhd 6. primary caregiver does not understand chinese
prehab - improving condition before surgery

Conditions: Cancer, Digestive System; Cancer, Rectum

Summary: the pilot research project is focused on the feasibility of a prehabilitation program for two groups of diagnoses (esophageal and stomach cancer, rectal cancer).

with the aim of achieving downstaging, downsizing, and reducing the risk of recurrence, neoadjuvant chemotherapy, possibly chemoradiotherapy - i.e. neoadjuvant therapy is indicated in the preoperative period for patients with cancer of the upper digestive tract and rectal cancer. chemotherapy has a negative impact not only on the overall physical and mental condition of the patient but also on the quality of life and on the daily activities of the individual, especially in the period when the organism is facing an abnormal stress load in the sense of extensive surgical procedures. recently, attention and efforts to improve postoperative morbidity and mortality have increasingly focused on the preoperative period. the concept of prehabilitation, which is defined as an intervention improving functional capacity before an upcoming physiological stressor, appears as a way to contribute to this. this fact is evidenced by a number of published references. the main aim of the study is to confirm or refute the feasibility of the prehabilitation program during neoadjuvant therapy in two diagnostic groups of patients: * - patients with cancer of the upper digestive tract * - patients with rectal cancer the prehabilitation program will be implemented in the patient's home environment. the study aims to answer the basic research question of whether selected patients will be able to complete a home exercise regimen during the preoperative period when they will undergo neoadjuvant therapy. as part of the study, the program's security and feasibility will be tested.

Eligibility criteria:
inclusion criteria: * radically operable locally advanced cancer of the esophagus, esophagogastric junction, stomach * radically operable locally advanced carcinoma of the rectum * the patient is able to handle the planned surgical resection procedure * planned preoperative neoadjuvant therapy * age \> 18 years * the ability to complete a spiroergometric examination * the ability to carry out a prehabilitation program consent to participate in the study confirmed by signing the informed consent exclusion criteria: * contraindications for spiroergometric examination * limitation on the part of the locomotor system to spiroergometric examination or daily exercise (e.g. amputation, severe gonarthrosis, coxarthrosis) * inoperability determined by the interdisciplinary team * inability to manage the planned operational performance * acute surgical performance * synchronous malignant disease * multivisceral resection * planned non-surgical therapeutic procedure * incomplete data

Keywords: prehabilitation cancer of the digestive system cancer of the rectum endurance walking power training
pcsk9 inhibitor treatment for patients with spg5

Conditions: Hereditary Spastic Paraplegia Type 5

Summary: spastic paraplegia type 5 (spg5) is a rare subtype of hereditary spastic paraplegia, a highly heterogeneous group of neurodegenerative disorders defined by progressive neurodegeneration of the corticospinal tract motor neurons. spg5 is caused by recessive mutations in the gene cyp7b1 encoding oxysterol-7a-hydroxylase. this enzyme is involved in the degradation of cholesterol into primary bile acids. cyp7b1 deficiency has been shown to lead to accumulation of neurotoxic oxysterols. oxysterols were found to impair metabolic activity and viability of human cortical neurons at concentrations found in spg5 patients, indicating that elevated levels of oxysterols might be key pathogenic factors in spg5. monoclonal antibodies that inhibit proprotein convertase subtilisin-kexin type 9 (pcsk9) have emerged as a new class of drugs that effectively lower cholesterol levels. evolocumab, a member of this class, is a fully human monoclonal antibody that reduces ldl cholesterol levels by approximately 60%. we thus performed this interventional trial with evolocumab 420 mg for spg5 patients.


Eligibility criteria:
inclusion criteria: * age 14-80 years * probands with clinically manifest hereditary spastic paraplegia * genetically confirmed diagnosis of spg5 exclusion criteria: * comprised treatment with statins 3 months prior to enrolment * contraindications to pcsk9 inhibitor therapy * pregnancy was excluded in women of childbearing age
effects of acute supplementation of citrus aurantium l. on the recovery of autonomic and cardiovascular activity after a sub-maximum aerobic exercise session in healthy individuals

Conditions: To Evaluate the Effect of Supplementation of Citrus Aurantium in Active Individuals

Summary: introduction: non-pharmacological interventions for the treatment of cardiovascular and metabolic disorders have been investigated. in this context, citrus aurantium l., popularly known as bitter orange, rich in synephrine (p-synephrine), a phenylethylaminic alkaloid that is present in the bitter orange peel, has been used as an adjunct in metabolic disorders. given the effects, the components of citrus aurantium l. diverge from other thermogens by being able to activate metabolism and lipolysis without interfering with the performance of the cardiovascular system, making this an advantage for its use in diets. in studies, it has been observed that the activation of β-3 receptors plays an important role in the regulation and activation of other receptors, modulating and, when they are stimulated in excess, and thus, it presents effects that in addition to not causing overload in the cardiovascular system. objective: to evaluate the effect of supplementation of citrus aurantium l. in combination with submaximal aerobic exercise on autonomic and cardiovascular parameters of physically active. methodology: this is a prospective, randomized, placebo-controlled, double-blind crossover trial. 40 physically active volunteers will participate in the study. they will be qualified for the voluntary study of the male gender, who are aged between 18 and 30 years old and have a body mass index (bmi) between 18.5 kg / m² and 29.9 kg / m². do not use any medication that may interfere with cardiac autonomic modulation and do not have skeletal muscle damage. they will be considered as exclusion criteria for clinical patients, as well as those who have already used anabolic steroids or who have cardiorespiratory, neurological disorders and other known impairments that prevent the subject from performing the procedures. expected results: speculated that the protective effects of flavonoids and their antioxidant properties found in citrus aurantium l., optimize autonomic recovery after aerobic exercise. in addition, hrv can be used to ascertain its sna activation effects and validate the safety of the applicability of this supplement for overweight populations, considering that it is used for this purpose.


Eligibility criteria:
inclusion criteria: * male volunteers, aged between 18 and 30 years and with a body mass index (bmi) between 18.5 kg / m² and 29.9 kg / m² will be considered eligible for the study. exclusion criteria: * smoking patients will be considered as exclusion criteria. as well as individuals with cardiorespiratory, neurological disorders and other known impairments that prevent the subject from performing the procedures.
adjuvant chemotherapy with paclitaxel and cisplatin in lymph node-positive adjuvant chemotherapy in the treatment of the lymph node positive thoracic esophageal squamous cell carcinoma

Conditions: Esophageal Cancer

Summary: esophageal cancer is a highly aggressive malignancy with a poor overall outcome. * five year survival rate after radical esophagectomy is modest at about 40%.the patients with regional lymph node metastases have worse outcome than those without lymph node metastases. * no standard postoperative adjuvant chemotherapy has ever been established.


Eligibility criteria:
inclusion criteria: * ability to give informed consent * histological proof of thoracic esophageal squamous cell carcinoma with negative proximal and distal margins * node-positive and pathologic stage m0 * eastern cooperative oncology group (ecog) performance status 0-1 * patients were enrolled 4 to 10 weeks after surgery * adequate organ function was required in 2 weeks of registration and was defined as: serum creatinine within normal institutional limit, and creatinine clearance (crcl) ≥60ml/minute. aspartate aminotransferase and bilirubin\<2 times of upper normal institutional limits exclusion criteria: * prior chemotherapy or concurrent radiation therapy before esophagectomy * r1 or r2 resection * clinically significant hearing loss or symptomatic peripheral neuropathy during initial examination

Keywords: esophageal cancer adjuvant chemotherapy esophageal surgery paclitaxel
selecting insulin analogs for closed-loop control using multiplex pharmacokinetic profiling

Conditions: Type 1 Diabetes

Summary: the investigators are doing this research study to compare the pharmacokinetics (pk) (rate of absorption) of insulin lispro (humalog), insulin aspart (novolog), and insulin glulisine (apidra) within individual subjects. additionally, the investigators will perform a preliminary feasibility evaluation of a minimally invasive continuous insulin monitoring (cim) device and its use to derive pk parameters in human subjects.


Eligibility criteria:
inclusion criteria: * age 18 years or older with clinical type 1 diabetes for at least five years * diabetes managed using an insulin infusion pump and rapid- or very-rapid-acting insulins including insulin aspart (novolog), insulin lispro (humalog), and insulin glulisine (apidra). * ability to consume a sufficient amount of carbohydrates over 2-3 hours to cover 9 units of rapid acting insulin exclusion criteria: * unable to provide informed consent * unable to comply with study procedures * inadequate venous access as determined by study nurse or physician at time of screening. * pregnancy * history of gastric banding, gastric bypass, or other gastrointestinal condition that may prevent a subject from consuming a normal sized meal * hemoglobin \<13.5 for men, \< 12 for women

Keywords: pharmacokinetics
identification of complete lymph node removal by application of near infrared fluorescence imaging in laparoscopic and robotic gastrectomy

Conditions: Gastric Cancer

Summary: lymph node dissection in gastric cancer surgery is a very important factor not only for exact acquisition of stage but also proper treatment. realistically, it is impossible to identify complete removal of lymph node in dissected nodal station by naked eye. the investigators can assess the route of lymphatic drainage and identify residual lymph nodes in dissected area. in the field of gastric cancer treatment, icg and near infra-red fluorescence imaging was used only detection of sentinel lymph nodes. however, this novel concept can help to understand lymphatic drainage and make surgeons to perform d1+ or d2 lymph node dissection completely.


Eligibility criteria:
inclusion criteria: 1. males or females, aged≥20 years and ≤80 years 2. eastern cooperative oncology group performance status (ecog ps) of 0 or 1 at study entry 3. american society of anesthesiolosists (asa) score of 1 to 3 4. histologically confirmed adenocarcinoma in stomach 5. clinical stage i (t1n0m0, t2n0m0, t1n1m0) 5. the patient has curatively resectable disease 6. the patient has given their written informed consent to participate in the study exclusion criteria: 1. m1 status 2. experience of previous gastric resection 3. complication due to gastric cancer, such as complete obstruction or perforation 4. history of anti-cancer therapy (chemotherapy or radiotherapy) for current gastric cancer 5. history of surgery, chemotherapy or radiotherapy for primary carcinoma of other organ in 5 years

Keywords: near infrared fluorescence imaging indocyanine green gastrectomy
impact of new interventional imaging modality use on patient radiation exposure in transarterial chemoembolization

Conditions: Hepatic Tumor

Summary: transarterial chemoembolization (tace) is the most performed endovascular interventional radiology (ir) procedure. tace procedures are performed in an ir suite, most of which are equipped with floor-based flat-panel robotic c-arm allowing two-dimensional imaging. cone-beam computed tomography (cbct) has been developed to allow three-dimensional navigation but has several limitations such as reduced signal to noise ratio and small field-of-view, and seems to have negative impact on patient radiation exposure. another option to perform 3d imaging is called angio-ct which combines a ct-scan and a floor-based flat-panel robotic c-arm in a single ir suite. even if some publications have shown benefit of angio-ct in tace procedures in japan, no study about angio-ct in liver ir procedures has been conducted in the occidental world so far. the purpose of our study was to assess the impact of angio-ct use on patient radiation exposure and treatment quality in tace procedures compared to cbct. this before-after study consisted of a review of consecutive tace procedures performed between january 2016 and september 2017 in our institution with two different imaging modalities, defining two study groups (c-arm with cbct versus angio-ct).


Eligibility criteria:
inclusion criteria: * age \> or = 18 years * primary or secondary liver tumor(s) * tace approved by multidisciplinary tumor meeting exclusion criteria: - tace not performed
short- and medium-term evaluation of mastoid filling using bioactive glass"

Conditions: Cholesteatoma

Summary: adult patients referred to the ent surgery department of the hospices civils de lyon with cholesteatoma that had never been operated on. all patients will benefit from surgical management for cholesteatoma initially in the operating room under general anesthesia. the surgical technique (closed technique) is the reference technique for the management of cholesteatoma in adults. it involves a cartilaginous removal to reconstruct the attical region. then a filling material is used to fill the mastoid (glassbone™ or bonalive™), and above all to stabilize the cartilaginous fragment to prevent a recurrence.

patients are operated on as an outpatient and receive a phone call the next morning to look for an initial complication. the patients will be reviewed in consultation at d8, d45, 3 months, 6 months and at 18 months with clinical examination (otoscopy) and audiometry at each consultation. the consultation on d8 is used for removal of the expandable cotton put in place in the external auditory canal (cae) during surgery to guide healing, control post-auricular healing and look for signs of complication during the examination. a cone beam (cbct) is performed during the consultation on d45 to confirm the correct position of the ossiculoplasty and check the persistence of the initial filling. the proportion of filled mastoid at d45 will serve as a reference to then be compared to the ct scan at 6 months and at 18 months. during surgery, and at the consultation at 6 months and 18 months, patients will also have to complete a quality of life questionnaire (chronic ear survey french version; in the appendix).

Eligibility criteria:
inclusion criteria: * patients at least 18 years old * patients with proven cholesteatoma * patient requiring and agreeing to surgery with filling of the mastoid or tympanic epi (closed technique with filling) * patient having a surgery with filling in first intention exclusion criteria: * background: * known outer, middle or inner ear malformation * congenital cholesteatoma * previously operated cholesteatoma * cholesteatoma requiring an open technique or presenting with chronic non-cholesteatomatous otitis * contraindications to the use of glassbone™ or bonalive™ * pregnant, parturient or nursing mothers * persons deprived of their liberty by a judicial or administrative decision, persons subject to psychiatric care, adults subject to a measure of legal protection or unable to express themselves * patient participating in interventional research excluding routine care research (old regulations) and category 2 research that does not interfere with the analysis of the primary endpoint * patient objecting to the use of their data